ORIC Pharmaceuticals, Inc. granted 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees who joined the company in August 2026. The inducement awards were granted on September 1, 2026, under the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan and require continued employment or service through the applicable vesting dates. The options carry an exercise price equal to ORIC’s closing share price on the grant date. Twenty-five percent of the option shares vest after one year, followed by monthly vesting of one-thirty-sixth of the remaining shares. One-third of the restricted stock units vest on each of the first three anniversaries. ORIC’s Compensation Committee approved the awards under Nasdaq Rule 5635(c)(4), which covers equity grants made as a material inducement to employment. The company is developing rinzimetostat for prostate cancer and enozertinib for non-small cell lung cancer, while warning that its development plans and other forward-looking statements face clinical, regulatory, funding, commercial and operational risks.